Pevonedistat - Takeda Oncology

Drug Profile

Pevonedistat - Takeda Oncology

Alternative Names: MLN-4924; Pevonedistat hydrochloride; TAK 924

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Children's Oncology Group; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Takeda Oncology; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Myeloproliferative disorders
  • Phase I/II Mesothelioma
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 28 Nov 2017 Phase-III clinical trials in Acute myeloid leukaemia (Combination therapy) in USA (IV) (NCT03268954)
  • 28 Nov 2017 Phase-III clinical trials in Chronic myelomonocytic leukaemia (Combination therapy) in USA (IV) (NCT03268954)
  • 28 Nov 2017 Phase-III clinical trials in Myelodysplastic syndromes (Combination therapy) in USA (IV) (NCT03268954)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top